- Home
- REGN vs FDX Comparison
REGN vs FDX Comparison
Compare REGN & FDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REGN
- FDX
- Stock Information
- Founded
- REGN 1988
- FDX 1971
- Country
- REGN United States
- FDX United States
- Employees
- REGN N/A
- FDX N/A
- Industry
- REGN Biotechnology: Pharmaceutical Preparations
- FDX Air Freight/Delivery Services
- Sector
- REGN Health Care
- FDX Consumer Discretionary
- Exchange
- REGN Nasdaq
- FDX Nasdaq
- Market Cap
- REGN 63.4B
- FDX 61.2B
- IPO Year
- REGN 1991
- FDX N/A
- Fundamental
- Price
- REGN $563.16
- FDX $207.55
- Analyst Decision
- REGN Buy
- FDX Buy
- Analyst Count
- REGN 23
- FDX 23
- Target Price
- REGN $971.57
- FDX $298.18
- AVG Volume (30 Days)
- REGN 1.1M
- FDX 2.7M
- Earning Date
- REGN 04-29-2025
- FDX 03-20-2025
- Dividend Yield
- REGN 0.16%
- FDX 2.66%
- EPS Growth
- REGN 10.27
- FDX N/A
- EPS
- REGN 38.34
- FDX 15.95
- Revenue
- REGN $14,202,000,000.00
- FDX $87,815,000,000.00
- Revenue This Year
- REGN $4.06
- FDX $0.80
- Revenue Next Year
- REGN $6.54
- FDX $3.16
- P/E Ratio
- REGN $14.69
- FDX $13.01
- Revenue Growth
- REGN 8.27
- FDX 0.34
- 52 Week Low
- REGN $525.99
- FDX $194.30
- 52 Week High
- REGN $1,211.20
- FDX $313.84
- Technical
- Relative Strength Index (RSI)
- REGN 37.15
- FDX 37.85
- Support Level
- REGN $544.50
- FDX $201.03
- Resistance Level
- REGN $575.20
- FDX $214.18
- Average True Range (ATR)
- REGN 28.44
- FDX 10.47
- MACD
- REGN -1.59
- FDX -0.82
- Stochastic Oscillator
- REGN 32.25
- FDX 25.77
About REGN Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals Inc discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).
About FDX FedEx Corporation
FedEx pioneered overnight delivery in 1973 and remains the world's largest express package provider. In its fiscal 2024, which ended in May, FedEx derived 47% of revenue from its express division, 37% from ground, and 10% from freight, its asset-based less-than-truckload shipping segment. The remainder came from other services, including FedEx Office, which provides document production/shipping, and FedEx Logistics, which provides global forwarding. FedEx acquired Dutch parcel delivery firm TNT Express in 2016, boosting its presence across Europe. TNT was previously the fourth-largest global parcel delivery provider.